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1. Introduction 
Myocardial infarction (MI) is an important cause of mortality around the world, resulting 
from an ischemic necrosis induced by a vascular occlusion. In general, MI occurs 
unexpectedly and the clinical syndrome previous to MI is difficult to detect. Animal models 
of MI are very useful in the study of prevention, diagnosis and therapy design for human 
MI [Smith & Nuttall., 1985]. MI induced by ligation of the left anterior descending coronary 
artery is the animal model most frequently used; however, the anesthesia and surgical 
procedures affect the conditions in which the infarction occurred [Wang et al., 2006]. 
Therefore, MI in animal models studies should be induced in conscious animals with intact 
reflexes for greater clinical relevance. Myocardial infarction induced by isoproterenol (ISO) 
using toxic concentration of this β-adrenergic agonist drug, originally described by Rona 
[Rona et al., 1959] has been used by several groups to study the cardiotoxic effects of this 
molecule [Stanton et al,1969]. This model becomes relevant if we consider that increased 
adrenergic activation plays a role as a trigger of acute myocardial infarction. In addition, the 
stress associated to MI in patients, increases catecholamine blood levels, which in turn, 
augment contraction force of the heart and ATP utilization favoring an energetic unbalance 
[Wallace & Klein, 1969, Ueba et al, 1973]. 
We have used ISO-induced MI, which is a non-invasive experimental model, to study the 
mechanisms involved in MI in the steps previous and posterior to infarction [Chagoya de 
Sánchez et al., 1997]. Myocardial lesions induced by ISO are related to its cardiac stimulating 
properties [Chappel et al.,1959]. Our group has characterized histological, physiological and 
biochemical alterations in a long term model (0-96h) of ISO administration to rats [Chagoya 
de Sánchez et al., 1997]. Animals treated with ISO showed an infarct-like damage of the 
circumferential type in the subendocardium at the apex region of the left ventricle that 
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occurred at 12-24h after ISO administration. MI lesion was defined by: 1) histological criteria 
looking for coagulative necrosis and fiber fragmentation, 2) physiological and biochemical 
criteria, 3) functionally by a continuous telemetric ECG recordings and 4) the increase of 
serum marker enzymes specific for myocardial damage. These results lead us to define three 
stages of myocardial damage induced by ISO, preinfarction (0-12 h), infarction (12-24 h) and 
postinfarction (24-96 h). 
During the physiological characterization of the ISO model, the first functional events 
observed after 2 minutes of ISO administration were a 70% increase in heart rate and a 40% 
and 30% decrease in diastolic and systolic blood pressure respectively, which lasted from 3 
minutes to 6 h after ISO administration, inducing a functional hypoxia that resulted in a MI. 
Ultra structural changes in mitochondria were evident from the first hour of treatment but 
functional alterations in isolated mitochondria, like oxygen consumption, respiratory 
quotient, ATP synthesis and membrane potential appeared at 6 h of drug administration. 
However, an important decrease in mitochondrial protein (50%) was noticed after 3 h of 
treatment and was maintained during the whole study, but the energy imbalance, reflected 
by a decrease in energy charge and in the creatine phosphate/creatine ratio, was observed 
after 30 minutes of the treatment. All these alterations reached a maximum at the onset of 
infarction. Partial recovery of some of these parameters was observed during post-infarction 
period (24-96h) but it was not the case for ATP synthesis, oxygen consumption, total 
adenine nucleotides, and mitochondrial protein [Chagoya de Sánchez et al., 1997]. These 
results showed the critical role of mitochondrial function in the energy unbalance at the 
onset of MI induced by ISO. 
Early changes in Ca2+ overload and their consequences are crucial in ISO cardiotoxicity 
[Fleckenstein et al.,1974, Bloom & Davis, 1972; Barry & Bridge, 1972]. Prolonged hypoxia 
and the inotropic action of ISO on the cardiac muscle make it very likely that oxidative 
stress and Ca2+ overload could be involved in the mechanism of ISO-induced MI. 
Deregulation of intracellular Ca2+ homeostasis modifies the cell redox state generating 
oxidative stress [Choudhary & Dudley, 2002]. Knowing that myocardial Ca2+ overload and 
oxidative stress are well documented effects of ISO-induced MI, we investigated the 
correlation between oxidative stress and intracellular calcium handling in our model [Díaz-
Muñoz et al., 2006]. Analysis of total calcium content in sub cellular fractions, revealed that 
the mitochondrial fraction presented a significantly elevated Ca2+ content (80%) after 30 
minutes of ISO treatment reaching a peak at 6h (220%) and returning towards normal values 
after the MI (24-48h). These results showed a good correlation with the energy unbalance 
previously commented. 
The oxidative stress in the ISO-induced myocardial infarction was evaluated studying lipid 
peroxidation, the free radical generating systems, antioxidant enzymes and the glutathione 
system [Díaz-Muñoz et al., 2006]. Oxyradical generation during myocardial ischemia occurs 
mainly through the xanthine oxidase and the activated neutrophils [Ray & MaCord, 1982; 
Reimer et al., 1989] In addition, ISO oxidation also generates superoxide anions [Yates et al., 
1981]. In our model, a large amount of superoxide anions are formed during the 
preinfarction phase by inhibition of superoxide dismutase and catalase, just after MI there is 
an increase in the activity of both enzymes inactivating the superoxide ion. The nitroradicals 
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during MI are related with nitric oxide formation quantified by the stable products nitrite 
and nitrates ions. Lipid peroxidation was clearly increased after 6-96 h of ISO treatment as a 
consequence of ion superoxide formation during the pre-infarction period And the nitric 
oxide (NO) generated throughout the experimental period. The glutathione cycle, studied 
by the content of GSH and GSSG and the activities of GSH-peroxidase and GSH-reductase, 
was decreased during the three stages of ISO-induced cardiotoxicity. Thus, confirming the 
importance of the oxidative stress generated by an increase in ROS and RNS as well as a 
decrease in antioxidant defenses in this experimental model, reaching a maximum at 24-48 h 
[Díaz-Muñoz et al., 2006]. 
Niric oxide is a small biological molecule generated as gaseous free radical that participates 
in multiple physiological and pathological processes. It is a very reactive molecule with a 
life span of a few seconds that diffuses freely across membranes. To date, NO is considered 
as an important messenger molecule. In 1987 Moncada’s group [Palmer et al., 1987] showed 
that the endothelium derived relaxing factor (EDRF) was the nitric oxide that is 
biosynthesized from L-arginine [Palmer et al., 1988]. Later on, it was shown that NO 
formation is not limited to vascular tissue but into numerous cells. Apparently, it is a 
general mechanism of intercellular communication in order to activate the guanylate cyclase 
[Berrazueta et al., 1990]. NO is also a main regulator of the immune activity and functions as 
neurotransmitter in the central nervous tissue as physiological messenger [Lowestein & 
Snyder,1992] but it also has an important cytotoxic activity in vivo [Kröncke et al., 1997]. 
Physiological NO is synthesized by the constitutive nitric oxide synthase (eNOS, or III) for 
short periods of time (seconds or minutes). Cytotoxic NO is synthetized by the inducible 
nitric oxide synthase (iNOS or II) which produces NO for large periods of time, hours or 
days [Laurent et al., 1996] as occurs in macrophages activation. 
NO action can be direct or indirect [Espey et al., 2000; Wink & Mitchell, 1998]. In the direct 
one, NO interacts rapidly with the biological blank as occurs in the activation of the 
guanylate cyclase. In this case, NO reacts directly with the iron of the hemo group of the 
active center of the enzyme generating GMPc, which activates a cGMP dependent protein 
kinase resulting in the relaxation of the smooth muscle and vasodilatation, diminished heart 
contraction and stimulation of ionic pumps [Ignarro, 1990; Kröncke, 1997]. On the other 
hand, indirect effects are related to oxygen and nitrogen reactive species generating 
peroxynitrites (ONOO-). These compounds are responsible for the cytotoxicity that induces 
DNA fragmentation or lipid oxidation. Peroxynitrtites induce damage of the I-IV segments 
of the respiratory chain in the mitochondria as well as damage of Mn dependent superoxide 
dismutase (SOD-Mn) increasing the generation of H2O2 and superoxide anion which results 
in a dysfunctional mitochondria [Brown, 1999]. NO in the extracellular medium will react 
with oxygen and water to form nitrites and nitrates. 
Nitric oxide is produced by three isoforms of nitric oxide synthases in the heart; endothelial 
(eNOS), inducible (iNOS) and neuronal (nNOS). Cardiac myocytes express the three 
isoforms although eNOS is mainly expressed in the endothelial cells. eNOS is constitutively 
expressed and can be stimulated with the increase of cytosolic calcium and phosphorylation 
[Cale & Bird, 2006]. In contrast, iNOS is a cytokine–inducible isoenzyme. In healthy heart, 
physiological amounts of NO may help to sustain cardiac inotropy [Krenek et al., 2009]. It is 
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our hypothesis that in the ISO-induced MI model, the hypotensive effect observed after ISO 
administration, in the preinfarct stage [Chagoya de Sánchez, 1997], is mediated by NO and 
might be critical for the MI development. The main goal of this study is to investigate the 
role of NO in the development of MI using an inhibitor of its synthesis L-NAME (nitro-L-
arginine methyl ester). We examined the relative role of eNOS and iNOS on IM-induced 
pathological changes of histological, physiological, biochemical and molecular parameters 
as well as energy state of heart. Preinfarction, infarction and postinfarction stages were 
analysed. 
2. Material and methods 
Enzymes, coenzymes, isoproterenol, L-NAME and the kits for the assessment of enzyme 
activities were from Sigma Chemical Co (St. Louis, MO). eNOS and iNOS antibodies were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). All other reagents were obtained 
from Merck (Mexico). 
2.1 Animal treatment 
Male Wistar rats (250-300g, body weight) were injected subcutaneously (s.c.) at 9 AM with a 
single dose of isoproterenol hydrochloride (67mg/kg body weight). Control animals were 
injected with saline solution. Animals were euthanized at 0.5, 1, 3, 6, 12, 24, 48, 72, and 96 h 
after treatment, with exception of the animals used for hemodynamic parameters by 
radiotelemetry. Blood samples were taken to obtain serum. A heart sample was used for 
histological studies; other sample was taken for perchloric extracts and for analysis of the 
expression of the nitric oxide synthases. Other set of experiments in similar conditions were 
performed for Langendorff preparations to evaluate NO formation. L-NAME was 
administered i.p. at the dose of 110 mg/kg of body weight one hour before the ISO 
treatments. All procedures were conducted in accordance to the Federal Regulation for 
Animal Care and Experimentation (Ministry of Agriculture, SAGAR, Mexico). 
2.2 Histological studies 
The heart was removed immediately after death and slices were cut from the apex, fixed 
with 10% neutral buffered formaline. After embedding tissue in paraffine 4 μm thickness 
sections were stained with hematoxilin-eosine and Masson’s trichrome. A qualitative 
evaluation was made with a light microscope considering elongation, ondulation of the 
fibers, formation of contractile bands as a characteristic of the pre infarction stage, and the 
presence o macrophages, fibroblasts and collagen fibers as a post infarction stage. 
2.3 Hemodynamic studies 
These parameters were studied by radiotelemetry in freely moving conscious animals with a 
Data Sciences International equipment (Brockway and Hassier 1993), using a TL11M2-C50-
PXT implant to monitor blood systolic and diastolic pressure, and heart rate. To implant 
transmitters, rats were anesthetized with an i.p. injection of ketamine plus xylazine at 80 and 
10 mg/kg body weight respectively, surgical conditions as previously described [Chagoya 
www.intechopen.com
 
Role of Nitric Oxide in Isoproternol-Induced Myocardial Infarction 
 
21 
de Sánchez et al., 1997]. Animals were allowed to recover at least for one week. Twenty 
four-hours recordings were taken as control of the parameters to be studied. Afterwards, 
ISO was s.c. administered. L-NAME was administered one hour before ISO administration 
in the corresponding groups. 
2.4 Biochemical studies 
Nitric oxide formation was measured in isolated perfused hearts as described previously 
[Suárez et al., 1999]. Briefly, animals were anesthetized with sodium pentobarbital (63 mg/ kg 
of body weight). The heart was removed and retrogradely perfused via a non-recirculating 
perfusion system at constant flow. Perfusion medium was Krebs-Henseleit solution 
equilibrated with 95% O2 -5% CO2 at 37oC and pH of 7.4, with 2μM oxihemoglobin solution for 
NO further quantification. Once the heart had been connected, it was maintained 30 minutes 
(perfusion flow rate of 25 ml/min for 5 minutes, then the following 25 minutes at 10 ml/min) 
and cardiac frequency was stabilized at 1 Hz. Perfusion flow rate was controlled by a 
peristaltic pump and 3 samples spaced by 5 minutes were taken from the coronary arteries. 
NO was measured indirectly in a double bean spectrophotometer (DW2000, SLM Aminco, 
Urban Illinois USA) quantifying the metahemoglobin produced as a function of NO generated 
in the coronary arteries [Kelm & Schrader, 1988]. NO serum levels were measured indirectly 
by the quantification of nitrites and nitrates ions with the Grieiss reagent [Shultz et al., 1991]. 
NO synthase activity was measured by monitoring the conversion of [3H]-Arginine to [3H]-
Citrulline using a NOS Activity Assay Kit (Cayman Chemical Co, Ann Arbor, MI) and [3H]-
Arginine (PerkinElmer, Inc, Boston, MA) according to the manufacturer´s instructions. Briefly, 
40 µg of heart homogenate were used for the assay, and the reaction was carried out for 30 min 
at 37 °C. Serum levels of myocardial-damage enzyme markers were measured from blood 
samples taken from the neck of the rat at the time of euthanasia. Creatine phosphokinase (CK) 
(EC2.7.3.2) and its heart isoenzyme (CK-MB), as well as alpha-hydroxybutyrate 
dehydrogenase (alpha-HBDH, EC 1.1.1.30) were determined using conventional diagnostic 
kits. Aspartate aminotransferase (AST, EC 2.6.1.1) and lactic dehydrogenase (LDH, EC1,1,1,27) 
were measured  by the method of Bergmeyer and Bernt [1965] and [Bergmeyer etal. 1965]. 
Energy metabolism in the heart was evaluated measuring adenine nucleotides ATP, ADP and 
AMP and energy parameters as total adenine nucleotides and energy charge. For adenine 
nucleotide determination, 300mg of the heart were extracted with 8% perchloric acid, after 
centrifugation the sample was neutralized with 4M K2 CO3 Adenine nucleotide were 
quantified by reversed-phase high performance liquid chromatography [Hoffman& Liao, 
1977]. Energy charge was calculated according to Atkinson [1968]. 
2.5 Protein expression by western blotting 
Apical part of the left ventricle were homogenized in 50 mM Tris, pH 7.4, 1mM EDTA, 
containing a mixture of protease inhibitors. Homogenates were centrifuged at 10,000 g for 15 
min, and the supernatant was used as whole cell protein. Protein samples (20 µg of 
protein/well) were electrophoresed in SDS-polyacrylamide gels and transferred to PDVF 
membranes. Membranes were blocked for 1 h with 5% nonfat dry milk in TBST (50 mM Tris, 
150 mM NaCl at pH 7.4, and 0.05% Tween 20). Proteins were detected by incubating 
membranes overnight at 4°C with the following primary antibodies: anti-eNOS and anti-iNOS 
from Santa Cruz Biotechnology (Santa Cruz, CA), anti-phospho-eNOS (Ser-1177) (Cell 
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Signaling Technology, Danvers, MA). Primary antibody binding was detected with the 
respective horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA). Densitometric analysis of bands was performed with the Quantity One 
software (Bio-Rad). 
3. Results 
3.1 Histological studies 
Histological evaluation of the myocardial lesion induced by isoproterenol treatment with 
and without L-NAME is shown on Table 1. The ISO-induced lesion is localized in the apical 
region of the left ventricle. In the presence of L-NAME, ISO-induced lesion maintained the 
same localization but it was extended to the subepicardial zone with less intensity. The pre-
infarct lesions; elongation and ondulation of the fibers and necrosis and contraction bands 
were prolonged for 24h. The infarct lesions persisted for 48 h and the post infarction 
initiated early at 24 h with a slight decrease. Although the damaged fibers were similar in 
both groups, no necrosis was observed at the pre infarction stage suggesting that acute 
phase of necrosis at 6 h observed in the ISO group decreased and was extended for a longer 
period in presence of L-NAME. A diminished presence of polymorphonuclear cells and 
macrophages indicates a minor cellular lesion in the group treated with L-NAME 
demonstrating a different histological profile for each group. 
 
Table 1. Histological evaluation of the myocardial lesion by isoproterenol (ISO) with and 
without L-NAME. Animals received an s.c. administration of ISO. L-NAME was 
administrated 1 hour before. They were euthanized after ISO administration. Total damage 
with ISO was taken as 100%. Score code is: (+)= 25%; (++)= 50%; (+++)= 75%; (-)= not 
observed. 
3.2 Physiological studies 
Blood pressure and heart rate were monitored continuously by telemetry, the results are 
shown in the Figure 1. To study the effect of L-NAME it was administered i.p. 1 h before 
ISO, its effect was detected in the pre-ISO lecture, the initial ISO effect was observed at time 
0. A) Heart rate shows a strong and immediate increase from 279 to 450 b.p.m. during the 
first minutes of ISO administration. A further small increase (20%) was observed in the 
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group of animals treated with L-NAME until 48h of treatment. B) Changes in systolic blood 
pressure show the hypotensive effect of ISO previously described (Chagoya de Sánchez et 
al., 1997). The group treated with L-NAME showed an increase in systolic pressure from 85 
to 155 mmHg. ISO administration induced a diminution towards normal values followed by 
an increase to 140mmHg at 3 h of treatment returning to control values at 24 h. C) Similar 
profile was observed with diastolic pressure but the hypertensive effect (180 mmHg) was 
more evident. L-NAME administration did not significantly affect the effect of ISO 
increasing the heart rate but significantly reduced the hypotensive effect of ISO. 
 
Fig. 1. In vivo effect of L-NAME on changes induced by isoproterenol on heart rate and 
blood pressure. Rats received (i.p) NAME one hour before isoproterenol injection (s.c) at 
time 0, as described in Material and methods. The response was monitored continuously by 
a telemetry system. C= Control, N= NAME and PI= Pre-ISO. A) Time course of the variation 
in heart rate (b.p.m.; beats per minute) B) Systolic pressure (mmHg) and C) Diastolic 
pressure (mmHg).  Values are from a representative experiment of five.  
3.3 Biochemical studies   
3.3.1 Marker enzymes of myocardial damage (CK, CK-MB, α-HBDH, AST, LDH)  
Were measured in serum of the experimental animals at the time of infarction that is at 12 h 
after ISO treatment in the presence or absence of L-NAME. Results are presented in the 
Table 2. ISO-induced cardiac lesions caused a 2 to 10-fold increase in marker enzymes 
including specific enzymes of cardiac origin like CK-MB which increased almost 4-fold with 
respect to its control values. Enzymes representative of cell necrosis, as LDH, showed a 
A 
C 
B 
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tenfold augmentation. Animals treated with L-NAME and ISO showed a significant 
reduction in the level of marker enzymes mainly CK-MB and LDH indicating diminished 
myocardial damage at that time in the group of animals treated with L-NAME. 
Enzymes 
Without 
treatment
ISO ISO/NAME 
CK 110 ± 9.2 
220 ± 23 
P < 0.005 
 80 ± 2.4  
P < 0.001 
CK MB 104 ± 6.5 
389 ± 50.0 
P < 0.001 
160 ± 3.5 
P < 0.005 
-HBDH 22 ± 1.9 50 ± 8.0 
P < 0.01
44 ± 3.9 
P < 0.5
AST 110 ± 7.0 
260 ± 16.8 
P < 0.001 
220 ± 10.0 
P < 0.1 
LDH 120 ± 5.6 
1 180 ± 13.0 
P < 0.001 
102 ± 2.0 
P < 0.001  
Table 2. Effect of isoproterenol and L-NAME on serum levels of marker enzymes of 
myocardial damage at the time of infarction (12h). Values are average activity of the 
different enzymes in serum samples of the rats (n=5) ± standard error. P value of the 
isoproterenol column represents a comparison with the control group without treatment 
and the P value of the ISO-NAME group is the significance of the L-NAME/ISO group vs. 
ISO group. 
3.3.2 Energy metabolism 
The influence of L-NAME on the changes in energy metabolism produced by isoproterenol 
(Chagoya de Sánchez et al., 1997) is shown in Table 3. Values at time 0 were obtained in 
animals without treatment. Values of the Pre-ISO group correspond to the group that 
received L-NAME treatment one hour before ISO administration. The energy unbalance 
generated by ISO treatment is clearly observed by the statistically significant decrease in 
ATP levels along the three stages of cardiotoxicity; pre infarction, infarction and post 
infarction, being more decreased at 24 h during the infarction period. These changes are also  
accompanied by a diminution of ADP and an increase in AMP levels resulting in low levels 
of total adenine nucleotides in the heart with decreased energy charge  (E.C.= [ATP]+ 1/2 
[ADP]/ [ATP]+[ADP]+[AMP] (AN = total adenine nucleotides), being 0.86 a normal value). 
Animals treated with L-NAME also presented an energy unbalance ATP and ADP levels 
were higher than those observed in the ISO group. AMP levels increased only at 3 and 6 h 
and an interesting observation is that during the pos infarction stage energy parameters 
(ATP, total adenine nucleotides and energy charge) recovered towards normal values. 
3.3.3 NO formation 
We evaluated NO release in isolated perfused hearts from experimental animals at different 
times of ISO treatment (Fig 2). An increase in NO release was observed since 0.5 h reaching 
a maximum at 6 and 12 h of ISO treatment. NO release levels returned to control values 
from 24 to 96 h. L-NAME inhibitory effect on ISO-induced NO release was evident since  
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Table 3. Effect of L-NAME on changes of rat heart adenine nucleotides in the ISO-induced 
infarction. AN (adenine nucleotides) is de sum of adenine nucleotides; EC, energy charge 
(ATP+1/2 ADP/AN) values are the means   SEM, n=4, *p<0.05 ISO vs. 0 or ISO/NAME vs. 
Pre-ISO, #p<0.05 ISO-NAME vs. ISO. 
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Fig. 2. Effects of isoproterenol and L-NAME on NO release. NO release in perfused hearts 
from treated rats at different times. Values are mean ± S.E n=5. Dark bars are isoproterenol 
treatment and gray bars L-NAME + isoproterenol.# p ≤ 0.05 ISO or ISO/NAME group vs 
Control (Time 0). * p ≤ 0.05 ISO/NAME group vs ISO. 
0.5h with a maximal effect at 6-12 h of ISO treatment. After this time, the amount of NO 
released was similar in both groups suggesting the end of the inhibitory effect of L-NAME. 
Fig 3, shows nitric oxide synthases activity of the constitutive form (eNOS) and the 
inducible form (iNOS). ISO treatment gradually increased the activity of both isoforms 
during the pre infarction and infarction period. The maximal increase was at 24 h for eNOS 
and 12 h for iNOS. After this time, during the postinfarction, there was an important 
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decrease on both isoforms. Animals treated with L-.NAME showed a gradual diminution of 
eNOS activity (3, 24 h). After this time the activities of the isoforms reach normal values. The 
increase in nitric oxide release during the pre infarction periods are the result of an increase 
in the activity of eNOS and iNOS and L-NAME decreased NO release by decreasing eNOS 
activity during the preinfarction-infarction stages since no significant change was observed 
in iNOS activity.  
Protein expression of constitutive and inducible NO synthases in the presence of ISO and 
ISO+ L-NAME are shown in Fig 4. Small changes in the eNOS protein expression were 
observed during the preinfarction stage and more important ones during the post infarction 
Decreased eNOS protein levels were evident at 3, 12, and 24 h in the presence of L-NAME 
and no appreciable changes during the post infarction. eNOS is activated by 
phosphorylation in serine 1177. An increase in p-eNOS was observed after ISO treatment 
(1,3,6 h) with a diminution at (12,24,h). Treatment with L-NAME markedly decreased p-  
 
Fig. 3. The activity of constitutive and inducible (eNOS, iNOS) nitric oxide synthases. Values 
shown represent typical results of one experiment. Four experiments were performed. 
 
Fig. 4. Western blot analysis of a representative experiment (from three) of eNOS, P-eNOS 
s1177, iNOS protein expression. 
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eNOs (S1177) at 3, 12, and 24 h. At 6h eNOS is phosphorylated and must be active, however, 
there is an important reduction in NO release in the presence of L-NAME. iNOS expression 
was not detected in the control group. However, after ISO treatment, there was a gradual 
increase until 12 h with an important decrease after infarction which reached almost the 
control value at 96 h. A similar profile was observed in the group treated with L-NAME 
with differences at 6, 12, 48, and 96 h. NO serum levels were measured indirectly 
quantifying nitrites and nitrates (Fig 5). Although the same tendency as in isolated perfused 
hearts was observed, increased NO release during infarction (12, 24 h) was more clearly 
observed in the ISO-NAME group. 
 
Fig. 5. NO2 + NO3 in serum from both groups. Values are the mean ± SE, n=3. 
* p values > 0.05 ISO/NAME group vs control (Time 0) 
4. Discussion 
The role of nitric oxide in cardiovascular diseases is complex and controversial, mainly due 
to its multiple physiological and pathological effects which depend on the amount of NO 
synthetized by the nitric oxide synthases, their allosteric modulators, the metabolic 
conditions of the cells, redox and energy state, and the different experimental models used. 
A major physiological role of nitric oxide is the regulation of vascular tone. In this case the 
activity of endothelial eNOS is crucial since endothelial dysfunction is characterized by 
impairment of nitric oxide bioavailability which induces hypertension and cardiovascular 
diseases [Török, 2008]. In pathological conditions there is an increase in oxidative stress. 
Nitric oxide reacts with superoxide (O2-) to produce peroxynitrites, highly cytotoxic nitrogen 
species, that induce DNA fragmentation, and damage of segments of the respiratory chain 
inducing dysfunctional mitochondria [Brown, 1999]. In the experimental model of 
myocardial infarction induced by isoproterenol studied here, we observed this dual actions 
of nitric oxide: 1) the marked diminution of systolic and diastolic pressure after 2 minutes of 
ISO treatment [Chagoya de Sanchez et al. 1997], suggesting the participation of the nitric 
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oxide and 2) the cytotoxic action reflected in energy unbalance, dysfunctional mitochondria, 
oxidative stress, with increased levels of nitrites and nitrates as indicative of NO formation 
[Díaz-Muñoz et al, 2006). 
In order to determine the role of nitric oxide in the ISO-induced MI, we used an inhibitor of 
endothelial nitric oxide synthase; L-NAME (NG-nitro-L-arginine methyl ester) [Sander et al. 
1999; Frandsen et al. 2001] and systolic and diastolic blood pressure and heart rate were 
evaluated (Fig 1). The drastic decrease in systolic and diastolic blood pressure caused by 
isoproterenol could be related to an increase in nitric oxide release due to an overexpression 
of eNOS induced by isoproterenol as previously described [Krenek et al. 2006]. This idea 
was confirmed by our results that clearly showed a marked increase in NO release after ISO 
administration during the pre infarction stage (0.5- 12 h). These results correlated with the 
increase in eNOS activity and protein expression of total eNOS. In addition, the activated 
form phosphorylated eNOS at Ser-1177 was increased during the pre infarction and 
infarction stages. During post-infarction phase, the expression of total and activated 
phosphorylated enzyme corresponds to a moderate increase in nitric oxide. This effect of 
isoproterenol is partially prevented by the presence of L-NAME and a decrease of 30 to 90% 
in NO release was observed (Fig2A). This reduction in NO release was also related to a 
decrease in eNOS activity and protein expression of total and phosphorylated (eNOS, P-
eNOSs1177. The  eNOS-mediated NO generation is a highly regulated cellular event with 
multiple regulatory factors such as gene expression, translational modifications, intracellular 
localization, cofactors and phosphorylation [Govers & Rabelink, 2001). This could be the 
case for the result obtained at 3h of ISO administration in which NO release was low with 
elevated activity and expression of total and active form of eNOS. Isoproterenol also 
induced an increase of iNOS activity from 1-12 h of treatment reaching control values at the 
post infarction stage. Treatment with L-NAME induced a non-significant decrease in its 
activity and expression. The decrease in NO release and inhibition of eNOS in the presence 
of L-NAME lead us to the conclusion that the increase in systolic and diastolic pressure (Fig 
1) contributes to improve heart function. The maintenance of the diastolic pressure is very 
important for a good perfusion of the heart through the coronary arteries. These effects were 
maintained throughout pre-infarction, infarction and post-infarction suggesting a decrease 
of cardiotoxicity induced by isoproterenol. This possibility was also tested measuring 
marker enzymes of myocardial damage in serum at the time of infarction (Table 1). The 
dramatic drop in CK-MB and LDH serum levels suggests that in the presence of L-NAME, 
the magnitude of myocardial damage was reduced. Previously it was shown that 
isoproterenol-induced MI is accompanied by a marked energetic unbalance through the 3 
cardiotoxicity periods with no recovery in the post infarction stage. An interesting finding 
was that in the presence of L-NAME, at 48 h of ISO treatment in the post infarction stage, 
induced a recovery of energy balance which occurred increasing ATP, total adenine 
nucleotides and energy charge (Table 2). The indirect assessment of nitric oxide in serum 
also reflects the increase in NO at the infarction stage and it is mainly generated by iNOS 
when inflammatory cytokine levels are elevated as previously suggested [Gaballa et al., 
1999]. Inhibition of eNOS by L-NAME blocks vessel dilation inducing a more extended 
lesion increasing the number of damaged cells. At same time, inflammatory cell migration 
diminishes by the vessel constriction induced by L-NAME resulting in less inflammation. 
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5. Conclusion 
In summary, the present study shows that NO plays an important role in the installation 
and progression of the myocardial infarction induced by isoproterenol. The increased 
generation of nitric oxide was evidenced from 0.5 h until 12h of isoproterenol administration 
these likely resulted from an increase in the activity of both eNOS and iNOS. The first action 
seem to be a consequence of isoproterenol triggered signaling cascade action on the enzyme 
and the second one from subsequent inflammatory processes. The increase in eNOS is 
responsible for the hypotensive effect of ISO decreasing the systolic and diastolic pressure 
since the first 2 minutes of its administration. The consequent hypoperfusion induced an 
energy unbalance possibly due to the chronotropic and inotropic effects of isoproterenol 
which generates an increase in energy consumption. These effects demand an increase in 
mitochondrial function generating oxidative stress with ion superoxide formation, which in 
the presence of NO, will generate peroxynitrites resulting in mitochondrial damage and 
cellular death. All above contribute to myocardial infarction and the dysfunctional 
mitochondria prevents recovery of energy balance at the post infarction stage. Experiments 
in the presence of L-NAME (NO inhibitor) clearly showed a diminution of the acute phase 
of infarct, the inflammatory process and the reduction of the hypotensive action of ISO. As a 
result, there was an important increase in diastolic pressure and perfusion of the heart 
through the coronary arteries, diminishing the oxidative stress and a recuperation of energy 
balance which contributed to ameliorate myocardial function. The infarction observed in the 
presence of L-NAME is likely involved by the inflammation process that is not affected 
significantly by L-NAME treatment. These results clearly show the action of NO in 
isoproterenol-induced myocardial infarction and suggest the importance to assess the role of 
NO in pre infarction and early post infarction stages in patients. It is possible that the 
therapeutic modulation of NO release might prevent the cytotoxic actions of the excessive 
NO release which facilitate the recovery of the patient at the post infarction stage. 
6. Clinical perspective 
Myocardial ischemia/reperfusion is the major threat to cardiac myocytes in acute 
myocardial infarction. In spite of early interventions like reperfusion therapy, myocardial 
damage can not be avoided. Consequently, additional options to enhance myocardial 
resistance to ischemia/reperfusion are needed.  Increasing nitric oxide action has been 
considered a possibility to enhance myocardial perfusion during myocardial infarction. 
However, nitric oxide action may lead to adverse effects. We now add data on the beneficial 
effect of inhibiting nitric oxide action by using L-NAME during development of myocardial 
infarction. Inhibition of nitric oxide release diminished the inflammatory process and 
reduced the hypotensive action of isoproterenol. As a result, there was an important 
increase in diastolic pressure and perfusion of the heart. These effects diminished the 
oxidative stress and helped to improve energy balance which contributed to better recovery 
of the myocardial function. Hence, increasing nitric oxide action as a therapeutic regimen in 
acute myocardial infarction is likely to be less successful if the distinct phases of myocardial 
infarction development are not considered. Undoubtedly, nitric oxide-modulation of 
coronary vessel tone is a therapeutic target in myocardial infarction. In the present work, we 
demonstrated that inhibition of nitric oxide action can be beneficial depending of the 
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infarction stage. Development of new therapeutic strategies focused to manipulate nitric 
oxide action in pre-infarction, infarction and post-infarction is necessary to alleviate this 
important cardiac disease. 
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